The purpose of the assay is to assess the safety of TRO19622 330 mg QD as add-on therapy to
riluzole 50 mg bid in the treatment of patients suffering from ALS, after completion of the
preceding clinical trial (TRO19622 CL E Q 1015-1) in an open label extension.